Author:
Ueno H,Kosuge T,Matsuyama Y,Yamamoto J,Nakao A,Egawa S,Doi R,Monden M,Hatori T,Tanaka M,Shimada M,Kanemitsu K
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Aapro MS, Martin C, Hatty S (1998) Gemcitabine—a safety review. Anticancer Drugs 9: 191–201
2. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson 3rd AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270–3275
3. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
4. Evans DB, Abbruzzese JL, Willett CG (1997) Cancer of the pancreas. In Cancer: Principles and Practice of Oncology (ed 6), De Vita VT Jr, Hellman S, Rosenberg SA (eds), Pp 1126–1162. Lippincott Williams and Wilkins: Philadelphia
5. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AF, Mackey JR (2009) Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer. Gastroenterology 136: 187–195
Cited by
384 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献